News

12 Questions to Ask About Peptide Therapy

Creator: Priya Raman, Health Writer
Published: 2026-09-24

Twelve questions worth bringing to a peptide visit, grouped by what they uncover: the evidence, the review status, your own health and the vial itself, with why each is asked and what a straight answer sounds like.

Priya Raman, Health Writer September 24, 2026 7 min read

The short version

The useful questions fall into four groups: what the specific peptide has been studied in, where its regulatory review stands, whether it fits your health and medicines, and who makes and labels the vial.
An August 2026 review of six popular peptides, including BPC-157, TB-500, CJC-1295 and ipamorelin, found about two in three of the published studies used animals; the human studies were a handful, most without robust controls.
As of September 22, 2026, the day this article was written, FDA had published no proposed rule after its July 2026 advisory meeting on peptide compounding; compounded peptides are not FDA-approved, and a licensed provider may still prescribe one.
WADA's 2027 Prohibited List, published September 21, 2026, still names BPC-157 and lists sermorelin, CJC-1295, tesamorelin and ipamorelin as prohibited at all times; a prescription is not a Therapeutic Use Exemption.
In test purchases of semaglutide sold online without a prescription, the vials measured 7.7% to 14.4% pure against a 99% label claim, and all contained endotoxin.

The most useful questions to ask about peptide therapy fall into four groups: what this particular peptide has been studied in, where its regulatory review stands, whether it fits your health and your other medicines, and who makes, labels and stands behind the vial. None of them is a test you pass or fail, and each has an answer that sounds straight and one that sounds like a sales pitch.

Here are twelve, with why each gets asked and what a good answer tends to sound like. The visit itself is covered in what to expect from your first visit.

Questions to ask about peptide therapy: the evidence and the status

1. What has this peptide been studied in: cells, animals or people?

"Studied" can mean a dish of cells, a group of rats or a controlled trial in people, and those are very different levels of confidence. A scoping review published in August 2026 in The American Journal of Sports Medicine looked at six popular peptides, including BPC-157, TB-500, CJC-1295 and ipamorelin. About two in three of the papers it found were animal studies, and the human work was "limited to a handful of investigations, most lacking robust controls."

A good answer names the tier plainly. "Mostly rat studies" is honest; a vague "the research is strong" isn't. Whether peptides are safe turns on the same distinction.

2. What would count as it working, and when would we check?

Different peptides move different things on different clocks. A blood marker such as IGF-1, a hormone that tracks growth-hormone activity, can shift within days, while body composition or a recovery goal is judged over months. A good answer names the outcome and the checkpoint up front. How long peptides take to work lays out those timelines.

3. Has this peptide ever been approved, and where does its review stand?

Most peptides prescribed this way, BPC-157, TB-500, CJC-1295 and ipamorelin among them, have never had a U.S.-approved product. An FDA advisory committee met on July 23–24, 2026 to review BPC-157, TB-500 and several other peptides for the list of ingredients compounding pharmacies may work from. As of September 22, 2026, the day this article was written, no proposed rule had appeared in the Federal Register, and FDA's page on that ingredient list still read "Content current as of: 05/14/2026." The FDA peptide decision follows the votes.

A good answer states it without spin. Status is a fact about a regulatory file, not a verdict on you: a licensed provider may still prescribe a compounded formulation, and that decision is between you and your doctor.

What to ask a peptide doctor about your own health

4. Does anything in my history rule this out?

For peptides that raise growth hormone, such as sermorelin or CJC-1295 with ipamorelin, the big three are cancer history, blood sugar and pregnancy. Tesamorelin, the only lab-made version of growth-hormone-releasing hormone with a current U.S. label, shows why: the Egrifta WR label, revised March 2025, rules out active cancer because growth hormone is "a known growth factor," rules out pregnancy, and warns about blood sugar: in its trials, 5% of people on the drug reached an HbA1c (a roughly three-month average of blood sugar) of 6.5% or higher by week 26, against 1% on placebo.

Those are Egrifta's label facts, not sermorelin's, and compounded peptides have no FDA label of their own. A good answer is specific about which of your conditions matters.

5. Do my other medicines, supplements and peptides matter?

The provider can only check for overlap they know about, including anything bought online or from another clinic. Diabetes medicines matter too: the same label notes that people with diabetes may need their glucose-lowering drugs adjusted. A good answer asks for the whole list, awkward parts included.

6. I get drug tested. Does a prescription change that?

It doesn't. As of September 22, 2026, the day this article was written, the World Anti-Doping Agency had published its 2027 Prohibited List the day before, to take effect January 1, 2027. It still names BPC-157 among its non-approved substances, lists TB-500 under growth factors, and lists sermorelin, CJC-1295, tesamorelin and ipamorelin under growth hormone releasing factors, all prohibited at all times.

Only a Therapeutic Use Exemption, a formal permission from an anti-doping body, changes an athlete's position, and a prescription isn't one. BPC-157 and drug testing explains more.

7. Is the provider licensed in my state?

A telehealth prescriber generally needs a license in the state where you are during the visit. A good answer is a name, a credential and a license you can look up yourself; how to check a telehealth doctor's license shows where.

Questions about the vial, the label and the pharmacy

8. Who makes it?

A prescribed peptide is prepared for you by a licensed U.S. compounding pharmacy. Its license and standards carry real weight, because compounded drugs "are not FDA-approved," in FDA's own words, and the agency does not verify their safety, effectiveness or quality before they reach patients. A good answer names the pharmacy of record and its state license. What a peptide compounding pharmacy does and how compounded medications are made cover the rest.

9. What exactly will arrive, and how is it stored and measured?

Some compounded peptides arrive as a powder to be mixed, others already in solution. Either way, the pharmacy label sets the storage temperature and the beyond-use date, the last day that preparation may be used. Measuring is where people slip: in 2024 FDA warned about dosing errors with compounded semaglutide, some requiring hospitalization, where mixing up milliliters, milligrams and "units" may have played a part.

A good answer covers the concentration, the syringe, the volume and a pharmacy number; how to store peptides and how to reconstitute peptides go further.

10. Why isn't a vial from a website the same thing?

Because nobody stands behind what's in it. Doping-control labs in Cologne and Oslo found versions of GHRP-2, GHRP-6 and ipamorelin in black-market products that each carried an extra amino acid, which makes each a different molecule from the one it resembles (Krug et al., Growth Hormone & IGF Research, 2018). When researchers bought semaglutide online without a prescription, the three vials that arrived measured 7.7% to 14.4% pure against a 99% label claim, and every one contained endotoxin, a bacterial residue (Ashraf et al., Journal of Medical Internet Research, 2024). Gray-market peptides covers the wider picture.

After you start: side effects and who hears about them

11. What side effects should I watch for, and who do I tell?

A good answer is specific to the peptide. For sermorelin, a 1999 review of the studies in children found brief facial flushing and pain where the shot went in were the most commonly reported effects (Prakash and Goa, BioDrugs). For peptides with thinner human data, an honest answer says how little is known.

It should also name who to tell: the prescriber, the pharmacy, and FDA's MedWatch program, which takes reports from patients directly; FDA's page notes a provider "is NOT required to report." How to report peptide side effects walks through it.

Is peptide therapy right for me? What the answers decide

12. What happens if the provider says no?

No prescription is written, and a careful service tells you why: a firm contraindication, a medicine conflict, missing records, or something another clinician should look at first. A decline is a clinical outcome, not a glitch, and a good answer points to the next sensible step.

The answers don't add up to a score. They tell the provider whether a peptide fits your history, which one, and what follow-up makes sense. A 2026 review in Sports Medicine, written partly to help clinicians talk peptides through with patients, notes that rigorous human safety data for many unapproved peptides are scarce. That gap is why the conversation matters.

Promise's peptides are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved.

A licensed provider reviews every request, and not everyone qualifies.

Common questions

What should I ask before starting peptide therapy?

The most useful questions cover what the peptide has been studied in (cells, animals or people), what would count as it working and when that gets checked, where its FDA review stands, whether anything in your history rules it out, which pharmacy makes it, how it is stored and measured, which side effects matter, who hears about them, and what happens after a decline.

Is peptide therapy FDA-approved?

Not the compounded formulations. Most peptides prescribed this way, including BPC-157, TB-500, CJC-1295 and ipamorelin, have never had a U.S.-approved product, and compounded preparations are not FDA-approved, which means FDA does not verify their safety, effectiveness or quality before use. A licensed provider may still prescribe one; that decision is between you and your doctor.

Does a prescription let athletes use peptides in tested sport?

It does not. WADA's 2027 Prohibited List, published September 21, 2026 and in force from January 1, 2027, still names BPC-157 and lists TB-500, sermorelin, CJC-1295, tesamorelin and ipamorelin as prohibited at all times. Only a Therapeutic Use Exemption, a formal permission from an anti-doping body, changes that, and a prescription is not one.

Why does a provider ask about cancer history before a growth-hormone peptide?

Because these peptides raise growth hormone, which the Egrifta WR (tesamorelin) label calls a known growth factor. That label rules out active cancer and pregnancy and warns about blood sugar: 5% of people on the drug reached an HbA1c of 6.5% or higher by week 26, against 1% on placebo. Those are tesamorelin's label facts, but they explain the questions.

How is a prescribed peptide different from one bought online?

It comes with a named prescriber, a licensed U.S. compounding pharmacy of record and a label stating what is in the vial. Online vials carry none of that. In one 2024 study, semaglutide bought without a prescription measured 7.7% to 14.4% pure against a 99% claim, and every vial contained endotoxin, a bacterial residue.

What happens if the provider says no to peptide therapy?

No prescription is written. A careful service explains the reason, whether a firm contraindication, a medicine conflict, missing records or something another clinician should assess first, and points to a sensible next step. A decline is a clinical outcome of the review, not a technical failure, and it often tells you something useful about your health.